Skip to main content

Table 6 Main histopathology findings of Sprague Dawley rats administration with subtilisin QK for 28-day and 28-day recovery

From: Safety assessment of subtilisin QK in rats

 

Male

Female

Control

25,000 FU/kg

Control

25,000 FU/kg

D28

D56

D28

D56

D28

D56

D28

D56

Lung, Pulmonary hemorrhage, limitations

3/10

0/5

1/10

0/5

1/10

0/5

1/10

0/5

Pancreas, Leaflet atrophy, limitations (slight)

0/10

0/5

1/10

0/5

0/10

0/5

0/10

0/5

Sialaden, Granular tube eosinophilic particle reduction (slight)

0/10

0/5

1/10

0/5

0/10

0/5

0/10

0/5

Ileum, Pei’s mineralization stove (slight)

0/10

0/5

2/10

0/5

0/10

0/5

0/10

0/5

Liver, Inflammatory cell infiltration, focal (slight)

1/10

0/5

1/10

1/5

0/10

1/5

0/10

0/5

Liver, Hepatic steatosis, lobular periphery

0/10

0/5

0/10

0/5

1/10

0/5

2/10

0/5

Kidney, Tubular basophilic lesion, focal (slight)

3/10

2/5

2/10

1/5

1/10

0/5

1/10

1/5

Bladder, mesenteric mineralization (slight)

0/10

0/5

1/10

0/5

0/10

0/5

0/10

0/5

Testicular, submucosal and interstitial hemorrhage, one side

0/10

0/5

1/10

0/5

Prostatic, interstitial lymphocytic infiltration

0/10

1/5

1/10

2/5

Eye, Retinal dysplasia (slight)

1/10

0/5

1/10

0/5

0/10

0/5

2/10

0/5

Harrington gland, Lymphocyte infiltration, one side (slight)

1/10

0/5

0/10

0/5

0/10

0/5

0/10

0/5